Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience

Melanoma and Skin CancerFurther Publications Immunology

Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status

Eur J Cancer

DeTemple VK, Ritter C, Srinivas N, Spassova I, Gambichler T, Hüning S, Gräger N, Gutzmer R, Bröcker EB, Ugurel S, Schrama D, Becker JC

doi: 10.1016/j.ejca.2024.115054

Melanoma and Skin Cancer

Sentinel lymph node biopsy versus observation in high-risk cutaneous squamous cell carcinoma in immunosuppressed and immunocompetent patients: An inverse probability of treatment weighting study

J Eur Acad Dermatol Venereol

Tejera-Vaquerizo A, Gómez-Tomás Á, Jaka A, Toll A, Del Río M, Ferrándiz-Pulido C, Fuente MJ, Carrasco C, Almazán-Fernández FM, Toledo-Pastrana T, Ferrer-Fuertes A, Ribero S, Avallone G, Cañueto J, Santos-Juanes J, Sanmartín O

doi: 10.1111/jdv.20051

Systemic Lupus Erythematosus

Modelling long-term outcomes for patients with systemic lupus erythematosus

Semin Arthritis Rheum

Touma Z, Kayaniyil S, Parackal A, Bonilla D, Su J, Johnston A, Gahn J, Hille ED, Ohsfeldt R, Chandran S

doi: 10.1016/j.semarthrit.2024.152507

Further Publications Rheumatology

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

BMJ Open

Weinblatt ME, Taylor PC, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Curtis P, Gupta A, Nijhawan R, O'Shea C, Rayner K, Saurigny D, Shelton C, Wang M, Wang R, Fleischmann RM

doi: 10.1136/bmjopen-2024-088869

Melanoma and Skin Cancer

Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas

JAMA Dermatol

Lo SN, Williams GJ, Cust AE, Ollila DW, Varey AHR, Ch'ng S, Scolyer RA, Thompson JF

doi: 10.1001/jamadermatol.2024.4900

Melanoma and Skin Cancer

SCQOLIT-SF: A revised outcome measure for assessing patient-reported outcomes in non-melanoma skin cancers

J Plast Reconstr Aesthet Surg

Jarratt Barnham I, Borsky K, Harrison C, Matin RN, Wali G, Burdon-Jones D, Gibbons K, Rodrigues J

doi: 10.1016/j.bjps.2025.01.030

Melanoma and Skin Cancer

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Melanoma Res

Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM

doi: 10.1097/CMR.0000000000001014

Melanoma and Skin Cancer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Lancet Oncol

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

doi: 10.1016/S1470-2045(24)00338-3

Melanoma and Skin Cancer

Baseline dermoscopic patterns predict long-term changes in nevus diameter and in dermoscopic features

J Eur Acad Dermatol Venereol

Reiter O, Mimouni T, Scope A, Kurtansky NR, Pastore L, Halpern AC, Marghoob AA

doi: 10.1111/jdv.20503

Related content

Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status

Sentinel lymph node biopsy versus observation in high-risk cutaneous squamous cell carcinoma in immunosuppressed and immunocompetent patients: An inverse probability of treatment weighting study

Modelling long-term outcomes for patients with systemic lupus erythematosus

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas

SCQOLIT-SF: A revised outcome measure for assessing patient-reported outcomes in non-melanoma skin cancers

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Baseline dermoscopic patterns predict long-term changes in nevus diameter and in dermoscopic features